Read by QxMD icon Read

81 mg aspirin

Xian Kang, Dennis Hong, Mehran Anvari, Maria Tiboni, Nalin Amin, Scott Gmora
BACKGROUND: Laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery is a safe and effective procedure for patients with severe obesity. One potential complication of LRYGB is the development of marginal ulcers (MUs). Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to significantly increase the likelihood of developing marginal ulcers after surgery. However, the risk associated with low-dose aspirin consumption is not well defined. We examined the impact of daily low-dose aspirin (81 mg) on the development of marginal ulcers following LRYGB...
December 1, 2016: Obesity Surgery
Yoshihiko Saito, Sadanori Okada, Hisao Ogawa, Hirofumi Soejima, Mio Sakuma, Masafumi Nakayama, Naofumi Doi, Hideaki Jinnouchi, Masako Waki, Izuru Masuda, Takeshi Morimoto
BACKGROUND: -The long-term efficacy and safety of low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes are still inconclusive. METHODS: -The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial was a randomized, open-label, standard-care controlled trial examining whether low-dose aspirin affected cardiovascular events in 2539 Japanese patients with type 2 diabetes and without pre-existing cardiovascular disease...
November 15, 2016: Circulation
Mark N Polizzotto, Thomas S Uldrick, Kathleen M Wyvill, Karen Aleman, Cody J Peer, Margaret Bevans, Irini Sereti, Frank Maldarelli, Denise Whitby, Vickie Marshall, Priscila H Goncalves, Vikram Khetani, William D Figg, Seth M Steinberg, Jerome B Zeldis, Robert Yarchoan
Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma-associated herpesvirus. Unmet needs include therapies that are oral, anthracycline sparing, and deliverable in resource-limited settings. We evaluated pomalidomide, an oral immune modulatory agent, in patients with symptomatic KS. Methods The primary objectives were to assess tolerability, pharmacokinetics, and activity. Initial dosage level was 5 mg once per day for 21 days per 28-day cycle, with a de-escalated level of 3 mg if not tolerable, and aspirin 81 mg once per day thromboprophylaxis...
December 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Kathryn A McInerney, Elizabeth E Hatch, Amelia K Wesselink, Kenneth J Rothman, Ellen M Mikkelsen, Lauren A Wise
STUDY QUESTION: To what extent is preconception use of pain-relieving medication associated with female fecundability? SUMMARY ANSWER: Women who used naproxen or opioids had slightly lower fecundability than women who did not use any pain-relieving medications; use of acetaminophen, aspirin and ibuprofen was not appreciably associated with fecundability. WHAT IS KNOWN ALREADY: Over-the-counter pain-relieving medications are commonly used by women of reproductive age in the USA...
November 5, 2016: Human Reproduction
Sunguk Jang, Tyler Stevens, Mansour A Parsi, Rocio Lopez, John J Vargo
BACKGROUND & AIMS: Biliary self-expandable metallic stents (SEMSs) are widely used to treat malignant and benign conditions of bile duct. Despite their lower rate of occlusion and longer patency than plastic stents, SEMSs still have significant rates of occlusion. We aimed to identify factors associated with occlusion of biliary SEMS. METHODS: We performed a retrospective study of consecutive patients who underwent endoscopic retrograde cholangiopancreatography with biliary SEMS placement at the Cleveland Clinic Foundation from March 2011 to April 2016...
October 17, 2016: Clinical Gastroenterology and Hepatology
Rose G Radin, Lindsey A Sjaarda, Neil J Perkins, Robert M Silver, Zhen Chen, Laurie L Lesher, Noya Galai, Jean Wactawski-Wende, Sunni L Mumford, Enrique F Schisterman
CONTEXT: Among women with a single, recent pregnancy loss, daily preconception low-dose aspirin (LDA) increased the live birth rate with no effect on pregnancy loss. The mechanism underlying this effect is unclear, but it may work through ovulation. OBJECTIVE: We estimated the effect of LDA on the per-cycle risk of anovulation among eumenorrheic women. DESIGN: The Effects of Aspirin in Gestation and Reproduction trial, a multi-center, randomized, double-blind, placebo-controlled trial of daily LDA on reproductive outcomes...
October 18, 2016: Journal of Clinical Endocrinology and Metabolism
Ling-Ling Peng, Yuan-Qi Zhao, Zi-Yi Zhou, Jing Jin, Min Zhao, Xin-Meng Chen, Ling-Yan Chen, Ye-Feng Cai, Jia-Li Li, Min Huang
AIM: Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events. Numerous evidence shows that thromboxane A2 receptor (TXA2 receptor, encoded by TBXA2R), lipoprotein-associated phospholipase A2 (Lp-PLA2, encoded by PLA2G7) and platelet endothelial aggregation receptor-1 (PEAR1, encoded by PEAR1) are crucial in regulating platelet activation, and P-glycoprotein (P-gp, encoded by MDR1) influences the absorption of aspirin in the intestine...
November 2016: Acta Pharmacologica Sinica
Stéphanie Roberge, Kypros Nicolaides, Suzanne Demers, Jon Hyett, Nils Chaillet, Emmanuel Bujold
BACKGROUND: Preeclampsia (PE) and fetal growth restriction (FGR) are major causes of perinatal death and handicap in survivors. Randomized clinical trials (RCTs) have reported that the risk of PE, severe PE and FGR can be reduced by the prophylactic use of aspirin in high-risk women, but the appropriate dose of the drug to achieve this objective is not certain. OBJECTIVE: To estimate the impact of aspirin dosage on the prevention of PE, severe PE and FGR. STUDY DESIGN: We performed a systematic review and meta-analysis of RCTs comparing the effect of daily aspirin or placebo (or no treatment) during pregnancy...
September 15, 2016: American Journal of Obstetrics and Gynecology
Marc P Bonaca, Shinya Goto, Deepak L Bhatt, P Gabriel Steg, Robert F Storey, Marc Cohen, Erica Goodrich, Laura Mauri, Ton Oude Ophuis, Mikhail Ruda, Jindřich Špinar, Ki-Bae Seung, Dayi Hu, Anthony J Dalby, Eva Jensen, Peter Held, David A Morrow, Eugene Braunwald, Marc S Sabatine
BACKGROUND: In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population...
September 20, 2016: Circulation
Paul Baciu, Candice M Nofar, Justin Spaulding, Hua Gao
PURPOSE: To report the occurrence of a branch retinal artery occlusion with paracentral acute middle maculopathy in an otherwise healthy young man with a history of livedo reticularis (LR). METHODS: Retrospective case report. PATIENTS: A 21-year-old man with a history of LR being treated with pentoxifylline developed an acute branch retinal artery occlusion with initial best-corrected visual acuity at presentation of 20/80. RESULTS: A thorough diagnostic work up was negative for potential causes of branch retinal artery occlusion or LR...
August 2, 2016: Retinal Cases & Brief Reports
Takafumi Ueno, Hiroshi Koiwaya, Ken-Ichiro Sasaki, Yoshio Katsuki, Yousuke Katsuda, Yoshinobu Murasato, Junichiro Shimamatsu, Kyoko Umeji, Yoritaka Otsuka, Tomohiro Kawasaki, Yoshisato Shibata, Yoshihiro Fukumoto
Patients with ischemic heart disease are administered a dual antiplatelet therapy after percutaneous coronary intervention. This consists of aspirin and thienopyridine, which can be switched from prasugrel to clopidogrel. However, the impact of switching is unknown. This study aimed to determine the efficacy and safety of switching from prasugrel to clopidogrel in Japanese patients. One-hundred and thirty-six patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention and patients with coronary artery disease requiring elective coronary stenting were enrolled...
August 3, 2016: Cardiovascular Intervention and Therapeutics
Abigail Johnston, W Schuyler Jones, Adrian F Hernandez
Coronary artery disease (CAD) is the underlying cause of death in one out of seven deaths in the USA. Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD. Despite a plethora of studies showing the benefit of aspirin in secondary prevention of cardiovascular events, debate remains regarding the optimal dose due to relatively small studies that had disparate results when comparing patients taking different aspirin dosages. More recently, aspirin dosing has been thoroughly studied in the CAD population with concomitant therapy (such as P2Y12 inhibitors); however, patients in these studies were not randomized to aspirin dose...
August 2016: Current Cardiology Reports
Vignesh T Packiam, Charles U Nottingham, Andrew J Cohen, Shane M Pearce, Arieh L Shalhav, Scott E Eggener
INTRODUCTION: Perioperative administration of aspirin for high-risk urologic procedures is controversial. We evaluated whether continuation of perioperative aspirin alters bleeding complications in patients who undergo robotic partial nephrectomy (RPN). MATERIALS AND METHODS: Retrospective review identified 214 consecutive patients who underwent RPN at our institution from May 2012 to March 2015. Comparisons were performed between 49 patients continuing aspirin (81 mg), 34 patients holding aspirin for at least 7 days before surgery, and 131 patients who had never taken aspirin...
September 2016: Journal of Endourology
Samia Mora, JoAnn E Manson
IMPORTANCE: Clinical decision making regarding the appropriate use of aspirin for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) events is complex, and requires an individualized benefit to risk assessment. OBJECTIVE: To review advances in the individualized assessment for ASCVD and bleeding risk, and to provide an update of the randomized clinical trial evidence that examined the use of aspirin for primary prevention (primarily for ASCVD, and secondarily for colorectal cancer)...
August 1, 2016: JAMA Internal Medicine
W K Kraft, J H Gilmartin, D L Chappell, F Gheyas, B M Walker, S Nagalla, U P Naik, J C Horrow, R E Wrishko, S Zhang, M S Anderson
The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two-period, open-label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady-state plasma concentrations equivalent to chronic 2.5 mg q.d. doses, for 7 days. In period 2, each group added 7 days of the therapy alternate to that of period 1 without washout. Bleeding time and platelet aggregation using arachidonic acid, ADP, and TRAP agonists were assessed...
August 2016: Clinical and Translational Science
Koji Matsuo, Sigita S Cahoon, Kosuke Yoshihara, Masako Shida, Mamoru Kakuda, Sosuke Adachi, Aida Moeini, Hiroko Machida, Jocelyn Garcia-Sayre, Yutaka Ueda, Takayuki Enomoto, Mikio Mikami, Lynda D Roman, Anil K Sood
OBJECTIVE: To examine the survival outcomes in women with endometrial cancer who were taking low-dose aspirin (81-100 mg/d). METHODS: A multicenter retrospective study was conducted examining patients with stage I-IV endometrial cancer who underwent hysterectomy-based surgical staging between January 2000 and December 2013 (N=1,687). Patient demographics, medical comorbidities, medication types, tumor characteristics, and treatment patterns were correlated to survival outcomes...
July 2016: Obstetrics and Gynecology
Daryl J Kor, Rickey E Carter, Pauline K Park, Emir Festic, Valerie M Banner-Goodspeed, Richard Hinds, Daniel Talmor, Ognjen Gajic, Lorraine B Ware, Michelle Ng Gong
IMPORTANCE: Management of acute respiratory distress syndrome (ARDS) remains largely supportive. Whether early intervention can prevent development of ARDS remains unclear. OBJECTIVE: To evaluate the efficacy and safety of early aspirin administration for the prevention of ARDS. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, double-blind, placebo-controlled, randomized clinical trial conducted at 16 US academic hospitals. Between January 2, 2012, and November 17, 2014, 7673 patients at risk for ARDS (Lung Injury Prediction Score ≥4) in the emergency department were screened and 400 were randomized...
June 14, 2016: JAMA: the Journal of the American Medical Association
Kiran Raj Pandey, David O Meltzer
BACKGROUND: Health expenditures are a major financial burden for many persons in low and middle-income countries, where individuals often lack health insurance. We estimate the effect of purchasing cardiovascular medicines on poverty in low and middle-income populations using rural and urban India as an example. METHODS: We created step-up treatment regimens for prevention of ischemic heart disease for the most common cardiovascular medications in India based on their cost and relative risk reduction...
2016: PloS One
Jorge L Gamboa, Jessica K Devin, Claudia E Ramirez, Chang Yu, Hui Nian, Rhonda H Lee, Nancy J Brown
A goal of aspirin therapy is to inhibit thromboxane production and platelet aggregation without inhibiting endothelial production of the vasodilator and anti-thrombotic prostacyclin. This study tested the hypothesis that extended-release aspirin (NHP-554C) would have increased selectivity for inhibition of basal and simulated thromboxane formation compared to immediate-release aspirin (ASA). Thirty-six healthy subjects were randomized to NHP-554C or ASA groups. Within each group, subjects were randomized to 5-day treatment with 81 mg/d, 162...
April 2016: Pharmacology Research & Perspectives
Francesco Franchi, Gabriel Todd Faz, Fabiana Rollini, Yongwhi Park, Jung Rae Cho, Estela Thano, Jenny Hu, Megha Kureti, Niti Aggarwal, Ashwin Durairaj, Latonya Been, Martin M Zenni, Luis A Guzman, Siva Suryadevara, Patrick Antoun, Theodore A Bass, Dominick J Angiolillo
OBJECTIVES: This study sought to assess the pharmacodynamic (PD) effects of switching to ticagrelor patients who were treated with prasugrel after undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome. BACKGROUND: In clinical practice, there is a frequent need to switch between P2Y12 receptor inhibitors. However, concerns on drug interactions have emerged when switching therapies. To date, the PD effects of switching from prasugrel to ticagrelor have yet to be investigated...
June 13, 2016: JACC. Cardiovascular Interventions
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"